Dr. Yair Levy
Texas Oncology–Baylor Charles A. Sammons Cancer Center
Dallas patients with chronic lymphocytic leukemia are benefiting from major advances in treatment. Targeted therapies have dramatically improved survival and quality of life.
Dr. Yair Levy
Texas Oncology–Baylor Charles A. Sammons Cancer Center
Learn why chemotherapy is no longer the standard treatment for most chronic lymphocytic leukemia (CLL) patients and how targeted therapies like BTK inhibitors are improving outcomes.
